Skip to content

About
Science
- FASN
- Posters/Publications
Investors & Media
Programs
Contact

About
Science
- FASN
- Posters/Publications
Investors & Media
Programs
Contact

PUBLICATIONS

NASH, Oncology, PUBLICATIONS, Virology

Demonstrating denifanstat’s differentiated approach in MASH with mechanistic and clinical data showing direct anti-fibrotic activity

By Graviton / 09/2024

8th Annual MASH Drug Development Summit

NASH, PUBLICATIONS

Combination of fatty acid synthase (FASN) inhibitor and thyroid hormone receptor beta (THRb) agonist resmetirom shows synergistic improvement of NAFLD activity score (NAS) within 6-weeks in diet-induced obese mice with biopsy-confirmed MASH

By charlie maddox / 06/2024

EASL International Liver Congress

NASH, PUBLICATIONS

Combination of fatty acid synthase (FASN) inhibitor and thyroid hormone receptor beta (THRb) agonist, resmetirom, improved markers of MASH and cardiovascular health in LDL receptor knockout MASH mice

By charlie maddox / 06/2024

EASL International Liver Congress

NASH, PUBLICATIONS

Denifanstat, a fatty acid synthase (FASN) inhibitor, shows significant fibrosis improvement and MASH resolution in FASCINATE-2, a Ph2b 52 week global, randomized, double blind, placebo-controlled trial in patients with F2 or F3 fibrosis

By charlie maddox / 06/2024

EASL International Liver Congress

Evaluation of FASN inhibitor & GLP-1 Combination in Preclinical Mouse Model

By Graviton / 11/2023

7th Obesity and NASH Drug Development Summit

NASH, PUBLICATIONS

Artificial Intelligence Based Digital Pathology Reveals Fatty Acid Synthase (FASN) Inhibitor Alone or in Combination with Semaglutide Improves Fibrosis in Diet-Induced Obese Mice with Biopsy-Confirmed NASH and Fibrosis

By Graviton / 11/2023

AASLD The Liver Meeting

NASH, PUBLICATIONS

Interim Analysis of FASCINATE-2 A Phase 2b Randomized, Placebo Controlled Trial Demonstrated Denifanstat Reduces Circulating Saturated Diacylglycerols and Triacylglycerols, Markers of Lipotoxicity

By Graviton / 11/2023

AASLD The Liver Meeting

Denifanstat, a fatty acid synthase (FASN) inhibitor for the treatment of biopsy-proven NASH: A 26-week interim analysis of the FASCINATE-2 Phase 2b trial

By Lehi Vidigal / 06/2023

EASL International Liver Congress

Phase II Investigation of TVB-2640 (denifanstat) with Bevacizumab in Patients with First Relapse High-Grade Astrocytoma

By Graviton / 04/2023

Clinical Cancer Research

Combination of fatty acid synthase inhibitor with tyrosine kinase inhibitors shows synergistic efficacy in HCC preclinical models, a novel potential approach for clinical development

By Graviton / 02/2023

HCC-TAG

Post pagination

← Previous 1 2 3 4 … 10 Next →

Site map

About
Science
Investors
Programs
Contact

About
Science
Investors
Programs
Contact

Contact us

Business Development
bd@sagimet.com

Investors
ir@sagimet.com

Media
media@sagimet.com

Human Resources
hr@sagimet.com

© 2025 Sagimet Biosciences. All Rights Reserved. Terms of Use Agreement | Privacy Policy | Clinical Trial Privacy Notice

About
Science
- FASN
- Posters/Publications
Investors & Media
Programs
Contact

About
Science
- FASN
- Posters/Publications
Investors & Media
Programs
Contact

Scroll to Top